Risk factors

INNOVATE Corp. faces ongoing going concern doubts driven by upcoming debt maturities and required asset sales under its 2027 Senior Secured Notes. Leadership changes continue following the unexpected passing of CEO Wayne Barr, while subsidiaries like DBMG and Pansend navigate operational and environmental hurdles.

Post-bankruptcy risks now center on realizing reorganization benefits and managing continuing uncertainty after the January 2025 emergence.

VirTra faces new operational risks from integrating immature artificial intelligence into law enforcement simulation products.

Energous added risks concerning international trade tariffs from Taiwan, cybersecurity vulnerabilities, and customer deployment complexities. Nasdaq listing compliance risks were dropped. Financial disclosures updated federal net operating loss carryforwards to approximately $340.0 million.

Worksport faces mounting going concern doubts with a net loss of $19.4 million and an accumulated deficit of $83.9 million.

Williams-Sonoma expanded its risk disclosures around e-commerce competition, third-party outsourcing dependencies, talent retention, and rising operational costs. The company also updated risks to account for AI integration in retail and evolving global tariff structures.

Capital-intensive data center operations rely heavily on power suppliers and hardware manufacturers for generative AI infrastructure.

Cash position improved to $3.8 million while convertible debt of $4.6 million was removed. Warrants decreased to 5.4 million and Series B preferred stock was added. Ongoing going concern doubts persist due to tobacco business losses.

Zentalis added risks covering the 2022 Inflation Reduction Act, EU pharmaceutical legislation revisions, and the January 2025 workforce reduction. The company faces heightened regulatory and pricing scrutiny under new political administrations.

Calisa Acquisition is a blank-check company with no revenues or operations, facing typical SPAC risks regarding redemptions and business combinations.

Accumulated deficit reached $501.5 million as of December 31, 2025, with ongoing reliance on additional funding.

Atossa Therapeutics faces substantial going concern doubts and requires significant additional capital to advance its lead drug, (Z)-endoxifen.